Table 5.
Levels of SOD, CAT, GSH, GSH-Px, T-AOC, MDA and NO in Serum and Liver Tissue (N=10/Group)
| Groups | SOD | CAT | GSH | GSH-Px | T-AOC | MDA | NO | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Serum (U/mL) |
Liver (U/mgprot) |
Serum (U/mL) |
Liver (U/mgprot) |
Serum (mgGSH/L) |
Liver (mgGSH/gprot) |
Serum (U/mL) |
Liver (U/mgprot) |
Serum (U/mL) |
Liver (U/mgprot) |
Serum (nmol/mL) |
Liver (nmol/mgprot) |
Serum (μmol/L) |
Liver (μmol/gprot) |
|
| Normal | 110.31±3.17bA | 16.91±0.2c | 32.35±1.4b | 33.18±0.12b | 10.14±1.05b | 2.53±0.27a | 57.36±11.39ab | 935.73±30.77a | 11.51±1.1b | 1.98±0.16b | 4.72±0.95b | 5.73±0.93d | 1.67±0.41b | 1.17±0.06ab |
| Model | 79.8±3.08c | 10.08±0.17d | 10.18±2.78c | 27.84±0.089a | 2.73±2.02d | 1.43±0.12c | 24.98±8.3c | 595.71±25.61c | 5.64±0.51d | 1.29±0.06d | 9.85±0.97a | 34.16±0.24a | 3.16±0.46a | 1.25±0.05a |
| Silymarin-L | 105.87±1.7b | 19.53±0.34b | 27.25±5.60b | 33.45±0.097b | 6.47±1.44c | 1.87±0.03b | 39.75±7.13bc | 688.89±45.35b | 8.79±0.79c | 1.69±0.05c | 4.56±0.81bc | 22.95±1.5b | 1.48±0.59b | 1.12±0.04bc |
| Silymarin-H | 119.51±3.04a | 22.09±0.32a | 41.33±3.32a | 40.95±0.28a | 12.95±1.06a | 2.46±0.02a | 70.94±18.3a | 992.44±44.35a | 14.19±1.26a | 2.17±0.07a | 3.09±0.43c | 11.73±0.62c | 1.15±0.69b | 1.04±0.03c |
Notes: Model, treated with D-Gal/LPS (250 mg/kg·bw and 25 mg/kg·bw) injection; silymarin-L: treated with silymarin (75 mg/kg·bw) oral administration; silymarin-H: treated with silymarin (150 mg/kg·bw) oral administration. a–dThere was significant difference in different letters in the same column (P < 0.05), which was determined by Duncan’s multiple range test. AValues presented are the mean±standard deviation (SD) of different organ coefficients.